Your browser doesn't support javascript.
loading
Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.
Röltgen, Katharina; Powell, Abigail E; Wirz, Oliver F; Stevens, Bryan A; Hogan, Catherine A; Najeeb, Javaria; Hunter, Molly; Wang, Hannah; Sahoo, Malaya K; Huang, ChunHong; Yamamoto, Fumiko; Manohar, Monali; Manalac, Justin; Otrelo-Cardoso, Ana R; Pham, Tho D; Rustagi, Arjun; Rogers, Angela J; Shah, Nigam H; Blish, Catherine A; Cochran, Jennifer R; Jardetzky, Theodore S; Zehnder, James L; Wang, Taia T; Narasimhan, Balasubramanian; Gombar, Saurabh; Tibshirani, Robert; Nadeau, Kari C; Kim, Peter S; Pinsky, Benjamin A; Boyd, Scott D.
Affiliation
  • Röltgen K; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Powell AE; Stanford ChEM-H and Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.
  • Wirz OF; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Stevens BA; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Hogan CA; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Najeeb J; Department of Structural Biology, Stanford University, Stanford, USA.
  • Hunter M; ATUM, Newark, CA, USA.
  • Wang H; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Sahoo MK; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Huang C; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Yamamoto F; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Manohar M; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University, Stanford, CA, USA.
  • Manalac J; Sean N. Parker Center for Allergy and Asthma Research, Stanford, CA, USA.
  • Otrelo-Cardoso AR; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Pham TD; Department of Structural Biology, Stanford University, Stanford, USA.
  • Rustagi A; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Rogers AJ; Stanford Blood Center, Palo Alto, CA, USA.
  • Shah NH; Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA.
  • Blish CA; Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University, Stanford, CA, USA.
  • Cochran JR; Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA.
  • Jardetzky TS; Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA.
  • Zehnder JL; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • Wang TT; Department of Bioengineering, Stanford University, Stanford, CA, USA.
  • Narasimhan B; Department of Structural Biology, Stanford University, Stanford, USA.
  • Gombar S; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Tibshirani R; Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA.
  • Nadeau KC; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • Kim PS; Department of Microbiology and Immunology, Stanford University, Stanford, CA, USA.
  • Pinsky BA; Department of Statistics, Stanford University, Stanford, CA, USA.
  • Boyd SD; Department of Biomedical Data Sciences, Stanford University, Stanford, CA, USA.
Sci Immunol ; 5(54)2020 12 07.
Article in En | MEDLINE | ID: mdl-33288645
ABSTRACT
SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, can neutralize the virus. It is, however, unknown which features of the serological response may affect clinical outcomes of COVID-19 patients. We analyzed 983 longitudinal plasma samples from 79 hospitalized COVID-19 patients and 175 SARS-CoV-2-infected outpatients and asymptomatic individuals. Within this cohort, 25 patients died of their illness. Higher ratios of IgG antibodies targeting S1 or RBD domains of spike compared to nucleocapsid antigen were seen in outpatients who had mild illness versus severely ill patients. Plasma antibody increases correlated with decreases in viral RNAemia, but antibody responses in acute illness were insufficient to predict inpatient outcomes. Pseudovirus neutralization assays and a scalable ELISA measuring antibodies blocking RBD-ACE2 interaction were well correlated with patient IgG titers to RBD. Outpatient and asymptomatic individuals' SARS-CoV-2 antibodies, including IgG, progressively decreased during observation up to five months post-infection.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Severity of Illness Index / COVID-19 / Antibodies, Viral Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Sci Immunol Year: 2020 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Severity of Illness Index / COVID-19 / Antibodies, Viral Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Sci Immunol Year: 2020 Document type: Article Affiliation country: United States